We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




PSA Assays Added to Tumor Marker Portfolio

By LabMedica International staff writers
Posted on 16 Dec 2008
A comprehensive tumor marker portfolio has added total prostate-specific antigen (PSA) assay and free PSA assays to its menu.

Prostate cancer is the second leading cause of cancer death in men. More...
Therefore, it is recommended that all men 50 or older be screened for prostate cancer by having an annual PSA test. If detected in its early stages, the 5-year survival rate for prostate cancer is nearly 100%.

Roche Diagnostics (Basel, Switzerland) has introduced the Elecsys total PSA and Elecsys free PSA assays to its immunoassay tumor marker menu for use on the Roche cobas 6000 analyzer series.

The advantages of the Roche Elecsys total and free PSA assays include better precision, an 18-minute turnaround time, and a convenient 20-μL-sample size for both assays. The tumor marker portfolio has a menu that already includes alpha fetal protein (AFP), carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9 (mainly used for pancreatic cancer), CA 15-3 (for monitoring breast cancer) and CA 125 (for ovarian cancer). Currently these assays are also available for use on the Roche Elecsys 2010 system and the Modular Analytics E 170 module.

Roche Diagnostics offers a broad portfolio of diagnostics tools that test for congestive heart failure, human immunodeficiency virus (HIV), Hepatitis B and C, fertility testing, diabetes, and many other diseases. This wide array of testing products and services is supplied to physicians, patients, hospitals, and laboratories.

Related Links:
Roche Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.